BR112021018262A2 - Tratamento de doenças e distúrbios mitocondriais associados, incluindo sintomas dos mesmos usando pridopidina - Google Patents
Tratamento de doenças e distúrbios mitocondriais associados, incluindo sintomas dos mesmos usando pridopidinaInfo
- Publication number
- BR112021018262A2 BR112021018262A2 BR112021018262A BR112021018262A BR112021018262A2 BR 112021018262 A2 BR112021018262 A2 BR 112021018262A2 BR 112021018262 A BR112021018262 A BR 112021018262A BR 112021018262 A BR112021018262 A BR 112021018262A BR 112021018262 A2 BR112021018262 A2 BR 112021018262A2
- Authority
- BR
- Brazil
- Prior art keywords
- pridopidine
- disorders
- treatment
- mitochondrial diseases
- including symptoms
- Prior art date
Links
- 208000012268 mitochondrial disease Diseases 0.000 title abstract 4
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 title abstract 3
- 229950003764 pridopidine Drugs 0.000 title abstract 3
- 208000024891 symptom Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004065 mitochondrial dysfunction Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
tratamento de doenças e distúrbios mitocondriais associados, incluindo sintomas dos mesmos usando pridopidina. a invenção exposta fornece um método para tratar um sujeito acometido por uma doença ou distúrbio associada à disfunção mitocondrial, compreendendo a administração ao sujeito de uma composição compreendendo pridopidina ou sal farmaceuticamente aceitável do mesmo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962818796P | 2019-03-15 | 2019-03-15 | |
| PCT/IL2020/050308 WO2020188558A1 (en) | 2019-03-15 | 2020-03-15 | Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021018262A2 true BR112021018262A2 (pt) | 2022-02-01 |
Family
ID=72520603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021018262A BR112021018262A2 (pt) | 2019-03-15 | 2020-03-15 | Tratamento de doenças e distúrbios mitocondriais associados, incluindo sintomas dos mesmos usando pridopidina |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210220342A1 (pt) |
| EP (1) | EP3937937A4 (pt) |
| JP (1) | JP7296472B2 (pt) |
| CN (1) | CN113597310A (pt) |
| AU (3) | AU2020243692B2 (pt) |
| BR (1) | BR112021018262A2 (pt) |
| CA (1) | CA3128250C (pt) |
| IL (1) | IL286268A (pt) |
| MX (1) | MX2021011269A (pt) |
| WO (1) | WO2020188558A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023062632A1 (en) * | 2021-10-11 | 2023-04-20 | Prilenia Neurotherapeutics Ltd. | Pridopidine and analogs thereof for the treatment of neurodegenerative eye disease |
| CN116472043A (zh) * | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
| EP4124338A1 (en) * | 2021-07-30 | 2023-02-01 | Université de Montpellier | Sigma-1 receptor activator for use in the treatment of a pathology associated with wfs1 mutation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140024677A1 (en) * | 2012-04-09 | 2014-01-23 | Musc Foundation For Research Development | Methods for inducing mitochondrial biogenesis |
| EP2900330A4 (en) * | 2012-09-27 | 2016-05-25 | Teva Pharma | LAQUINIMOD AND PRIDOPIDINE FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES |
| TW201613859A (en) * | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| WO2016138130A1 (en) * | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Use of pridopidine to improve cognitive function and for treating alzheimer's disease |
| EP3419622B1 (en) * | 2016-02-24 | 2024-03-06 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
| US11760733B2 (en) * | 2017-04-23 | 2023-09-19 | Washington University | Small molecule regulators of mitochondrial fusion and methods of use thereof |
| WO2018207193A1 (en) * | 2017-05-11 | 2018-11-15 | Hadasit Medical Research Services And Development Ltd. | Radiolabeled compounds that target organic cation transporters and uses thereof in radioimaging |
| WO2018207192A1 (en) * | 2017-05-11 | 2018-11-15 | Ramot At Tel-Aviv University Ltd. | Methods of treating leukodystrophies |
-
2020
- 2020-03-15 AU AU2020243692A patent/AU2020243692B2/en active Active
- 2020-03-15 CN CN202080021165.0A patent/CN113597310A/zh active Pending
- 2020-03-15 WO PCT/IL2020/050308 patent/WO2020188558A1/en active Application Filing
- 2020-03-15 MX MX2021011269A patent/MX2021011269A/es unknown
- 2020-03-15 BR BR112021018262A patent/BR112021018262A2/pt not_active Application Discontinuation
- 2020-03-15 CA CA3128250A patent/CA3128250C/en active Active
- 2020-03-15 JP JP2021555317A patent/JP7296472B2/ja active Active
- 2020-03-15 EP EP20773893.1A patent/EP3937937A4/en active Pending
-
2021
- 2021-02-23 US US17/182,605 patent/US20210220342A1/en active Pending
- 2021-09-09 IL IL286268A patent/IL286268A/en unknown
-
2023
- 2023-06-01 AU AU2023203435A patent/AU2023203435A1/en active Pending
- 2023-06-01 AU AU2023203434A patent/AU2023203434A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020188558A1 (en) | 2020-09-24 |
| AU2020243692A1 (en) | 2021-10-07 |
| EP3937937A4 (en) | 2022-11-23 |
| CA3128250C (en) | 2024-01-16 |
| AU2020243692B2 (en) | 2023-03-02 |
| IL286268A (en) | 2021-10-31 |
| US20210220342A1 (en) | 2021-07-22 |
| EP3937937A1 (en) | 2022-01-19 |
| JP7296472B2 (ja) | 2023-06-22 |
| JP2022525602A (ja) | 2022-05-18 |
| AU2023203434A1 (en) | 2023-06-29 |
| MX2021011269A (es) | 2021-10-01 |
| AU2023203435A1 (en) | 2023-06-29 |
| CA3128250A1 (en) | 2020-09-24 |
| CN113597310A (zh) | 2021-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019010646A2 (pt) | métodos de tratamento de condições inflamatórias | |
| BR112021018262A2 (pt) | Tratamento de doenças e distúrbios mitocondriais associados, incluindo sintomas dos mesmos usando pridopidina | |
| EA202190661A1 (ru) | Агонисты фарнезоидного х-рецептора для лечения заболевания | |
| BR112017008093A2 (pt) | processos para tratamento de doenças oculares | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| EA201890891A1 (ru) | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение | |
| EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
| CR20190468A (es) | Métodos para tratar enfermedades y trastornos mediados por completo | |
| BR112014004845A2 (pt) | pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| EA201490277A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| AR115583A1 (es) | Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado | |
| BR112015016282A2 (pt) | crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado | |
| CL2020002465A1 (es) | Método de tratamiento de enfermedad fibrótica | |
| BR112019002730A2 (pt) | acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa | |
| BR112019005985A2 (pt) | composições de combinação compreendendo agonistas de fxr para tratar ou prevenir uma doença ou distúrbio fibrótico, cirrótico | |
| CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
| MX2019012086A (es) | Composiciones y métodos para tratar o prevenir trastornos relacionados con la permeabilidad intestinal. | |
| MX2019009586A (es) | Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal. | |
| BR112022007595A2 (pt) | Métodos para tratar doença de alzheimer | |
| CL2019000625A1 (es) | Combinación de agonistas de fxr. | |
| EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
| BR112023021131A2 (pt) | Tratamento de tremor essencial | |
| BR112022000231A2 (pt) | Novos métodos | |
| BR112019025578A2 (pt) | Mesembrenol e/ou mesembranol para profilaxia e tratamento de pacientes que sofrem de epilepsia e doenças associadas | |
| MX2023002997A (es) | Metodo de tratamiento de la amiloidosis. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |